Allegro Ophthalmics Receives FDA Agreement Under Special Protocol Assessment (SPA) for Phase 2b/3 Clinical Trial of Risuteganib for the Treatment of Intermediate Dry AMD

April 12, 2023 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off on Allegro Ophthalmics Receives FDA Agreement Under Special Protocol Assessment (SPA) for Phase 2b/3 Clinical Trial of Risuteganib for the Treatment of Intermediate Dry AMD

- Intermediate Dry AMD Treatment Is a Significant Unmet Need - Mitochondrial Stabilizing Candidate Risuteganib Has Shown Best Corrected Visual Acuity Gains in Dry AMD Patient Population SAN JUAN CAPISTRANO, Calif., April 12, 2023 /PRNewswire/ -- Allegro Ophthalmics, LLC, a privately held...

Click to view original post